We provide you with 20 years of free, institutional-grade data for RCKT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of RCKT. Explore the full financial landscape of RCKT stock.
Total insider purchase within 3 month on this page: $34,100
Total insider selling within 3 month on this page: -$118,330
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Wilson Martin | Grant, award...etc | 150,000 | 2025-09-09 | ||
| Militello John | Grant, award...etc | 40,000 | 2025-09-09 | ||
| Schwartz Jonathan David | Grant, award...etc | 80,000 | 2025-09-09 | ||
| Bjork Elisabeth | Open Market Purchase | 10,000 | $3.41 | 2025-08-27 | |
| Militello John | Sale | -1,060 | $3.06 | $3,249 | 2025-08-20 |
| Schwartz Jonathan David | Sale | -2,485 | $3.06 | $7,617 | 2025-08-20 |
| Shah Gaurav | Sale | -2,234 | $3.05 | $6,814 | 2025-08-20 |
| Wilson Martin | Sale | -1,592 | $3.06 | $4,879 | 2025-08-20 |
| Schwartz Jonathan David | Sale | -11,161 | $3.02 | $33,695 | 2025-08-18 |
| Militello John | Sale | -7,043 | $3.02 | $21,263 | 2025-08-18 |
| Wilson Martin | Sale | -12,109 | $3.02 | $36,557 | 2025-08-18 |
| Stevens Christopher James | Grant, award...etc | 407,166 | 2025-08-06 | ||
| Pratumsuwan Piratip | Grant, award...etc | 30,000 | 2025-07-18 | ||
| Makker Gotham | Grant, award...etc | 49,434 | 2025-07-18 | ||
| BOESS CARSTEN | Grant, award...etc | 30,000 | 2025-07-18 | ||
| Malik Fady Ibraham | Grant, award...etc | 30,000 | 2025-07-18 | ||
| Bjork Elisabeth | Grant, award...etc | 30,000 | 2025-07-18 | ||
| SOUTHWELL DAVID P | Grant, award...etc | 30,000 | 2025-07-18 | ||
| GRANADILLO PEDRO P | Grant, award...etc | 54,734 | 2025-07-18 | ||
| WONG RODERICK | Grant, award...etc | 47,667 | 2025-07-18 | ||
| Dolsten Mikael | Grant, award...etc | 30,000 | 2025-07-18 | ||
| Ondrey Aaron | Sale | -1,477 | $2.88 | $4,257 | 2025-07-08 |
| Wilson Martin | Sale | -587 | $6.45 | $3,784 | 2025-05-22 |
| Shah Gaurav | Sale | -2,253 | $6.45 | $14,523 | 2025-05-22 |
| Schwartz Jonathan David | Sale | -801 | $6.45 | $5,163 | 2025-05-22 |
| Militello John | Sale | -357 | $6.45 | $2,301 | 2025-05-22 |
| Patel Kinnari | Sale | -767 | $6.45 | $4,944 | 2025-05-22 |
| Wilson Martin | Sale | -946 | $6.53 | $6,175 | 2025-05-20 |
| Patel Kinnari | Sale | -1,409 | $6.53 | $9,198 | 2025-05-20 |
| Shah Gaurav | Sale | -3,621 | $6.53 | $23,638 | 2025-05-20 |
| Schwartz Jonathan David | Sale | -1,582 | $6.53 | $10,327 | 2025-05-20 |
| Militello John | Sale | -655 | $6.53 | $4,276 | 2025-05-20 |
| Militello John | Sale | -718 | $7.16 | $5,139 | 2025-04-24 |
| Shah Gaurav | Open Market Purchase | 20,000 | $5.08 | 2025-04-14 | |
| Patel Kinnari | Open Market Purchase | 21,099 | $4.7 | 2025-04-10 | |
| Ondrey Aaron | Sale | -7,489 | $5.29 | $39,647 | 2025-04-08 |
| Schwartz Jonathan David | Sale | -15,093 | $23.35 | $352,422 | 2025-02-27 |
| Patel Kinnari | Sale | -6,078 | $10.58 | $64,305 | 2025-02-25 |
| Shah Gaurav | Sale | -16,303 | $10.58 | $172,486 | 2025-02-25 |
| Militello John | Sale | -2,737 | $10.58 | $28,957 | 2025-02-25 |
| Wilson Martin | Sale | -3,222 | $10.58 | $34,089 | 2025-02-25 |
| Ondrey Aaron | Grant, award...etc | 90,358 | 2025-02-13 | ||
| Wilson Martin | Grant, award...etc | 90,358 | 2025-02-13 | ||
| Militello John | Grant, award...etc | 20,080 | 2025-02-13 | ||
| Schwartz Jonathan David | Grant, award...etc | 80,318 | 2025-02-13 | ||
| Patel Kinnari | Grant, award...etc | 57,786 | 2025-02-13 | ||
| Shah Gaurav | Grant, award...etc | 81,655 | 2025-02-13 | ||
| Militello John | Sale | -896 | $10.38 | $9,300 | 2025-01-27 |
| Wilson Martin | Sale | -1,175 | $13.05 | $15,338 | 2024-11-25 |
| Patel Kinnari | Sale | -4,588 | $13.05 | $59,892 | 2024-11-25 |
| Shah Gaurav | Sale | -11,091 | $13.05 | $144,782 | 2024-11-25 |
| Militello John | Sale | -1,224 | $13.05 | $15,978 | 2024-11-25 |
| Militello John | Sale | -917 | $16.63 | $15,245 | 2024-11-04 |
| White Mark Andrew | Sale | -3,080 | $16.63 | $51,205 | 2024-11-04 |
| Patel Kinnari | Sale | -3,989 | $18.5 | $73,812 | 2024-08-20 |
| Wilson Martin | Sale | -1,027 | $18.5 | $19,004 | 2024-08-20 |
| Militello John | Sale | -1,064 | $18.5 | $19,688 | 2024-08-20 |
| Shah Gaurav | Sale | -9,650 | $18.5 | $178,564 | 2024-08-20 |
| Militello John | Sale | -812 | $23.02 | $18,688 | 2024-07-24 |
| White Mark Andrew | Sale | -3,026 | $20.39 | $61,715 | 2024-07-09 |
| Makker Gotham | Sale | -274,000 | $28.43 | $7,790,943 | 2024-06-10 |
| Patel Kinnari | Sale | -4,046 | $23.35 | $94,474 | 2024-05-20 |
| Patel Kinnari | Derivatives Exercise | 9,543 | 2024-05-20 | ||
| Wilson Martin | Sale | -1,048 | $23.35 | $24,471 | 2024-05-20 |
| Wilson Martin | Derivatives Exercise | 2,420 | 2024-05-20 | ||
| Shah Gaurav | Sale | -9,790 | $23.35 | $228,597 | 2024-05-20 |
| Shah Gaurav | Derivatives Exercise | 17,662 | 2024-05-20 | ||
| Militello John | Sale | -1,079 | $23.35 | $25,195 | 2024-05-20 |
| Militello John | Sale | -833 | $22.87 | $19,051 | 2024-04-24 |
| SOUTHWELL DAVID P | Sale | -80,000 | $24.22 | $1,937,920 | 2024-04-16 |
| SOUTHWELL DAVID P | Derivatives Exercise | 99,624 | 2024-04-16 | ||
| White Mark Andrew | Sale | -12,532 | $24.64 | $308,763 | 2024-04-10 |
| Ondrey Aaron | Grant, award...etc | 46,781 | 2024-04-03 | ||
| Schwartz Jonathan David | Initial | 2024-04-03 | |||
| Militello John | Sale | -2,490 | $28.1 | $69,979 | 2024-03-25 |
| Makker Gotham | Sale | -274,000 | $28.43 | $7,790,943 | 2024-03-25 |
| Militello John | Sale | -10,000 | $29.84 | $298,450 | 2024-03-04 |
| Militello John | Derivatives Exercise | 10,000 | 2024-03-04 |
The information provided in this report about RCKT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Rocket Pharmaceuticals, Inc(NASDAQ:RCKT) 
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect i...
Website: http://www.rocketpharma.com
Founded: 1999
Full Time Employees: 84
Sector: Healthcare
Industry: Biotechnology